Sanofi $SNY Position Raised by Adage Capital Partners GP L.L.C.

Key Points

• Adage Capital Partners GP L.L.C. increased its holdings in Sanofi by 5.0% during the first quarter, owning 504,671 shares valued at approximately $27.99 million.
• Sanofi's quarterly earnings report indicated an EPS of $0.90, missing analyst expectations, with a revenue of $11.34 billion, which was down 7.0% year-over-year.
• Analysts have a consensus rating of "Buy" for Sanofi, with a target price averaging $62.00, following upgrades from several firms including Deutsche Bank and JPMorgan.

Adage Capital Partners GP L.L.C. grew its position in Sanofi (NASDAQ:SNY - Free Report) by 5.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 504,671 shares of the company's stock after buying an additional 24,255 shares during the quarter. Adage Capital Partners GP L.L.C.'s holdings in Sanofi were worth $27,989,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. Cardinal Capital Management increased its position in shares of Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after buying an additional 199 shares in the last quarter. Gradient Investments LLC grew its holdings in shares of Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock worth $542,000 after buying an additional 200 shares in the last quarter. Perigon Wealth Management LLC raised its position in shares of Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after buying an additional 201 shares during the last quarter. Capital Analysts LLC lifted its stake in shares of Sanofi by 14.0% during the first quarter. Capital Analysts LLC now owns 1,664 shares of the company's stock valued at $92,000 after buying an additional 204 shares during the period. Finally, Beacon Financial Group boosted its holdings in shares of Sanofi by 1.6% during the first quarter. Beacon Financial Group now owns 14,398 shares of the company's stock worth $799,000 after purchasing an additional 222 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Up 2.6%

NASDAQ SNY traded up $1.17 during mid-day trading on Friday, reaching $46.50. 7,259,330 shares of the company's stock traded hands, compared to its average volume of 2,563,254. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The company has a fifty day simple moving average of $48.81 and a 200-day simple moving average of $51.38. The company has a market cap of $114.18 billion, a price-to-earnings ratio of 11.31, a P/E/G ratio of 1.10 and a beta of 0.51.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same period in the previous year, the business posted $1.73 EPS. The firm's quarterly revenue was down 7.0% compared to the same quarter last year. As a group, equities research analysts expect that Sanofi will post 4.36 EPS for the current year.

Analyst Ratings Changes

SNY has been the topic of a number of research analyst reports. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft raised Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Morgan Stanley set a $56.00 price target on Sanofi in a research note on Monday, June 2nd. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a report on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.